Intralesional treatment of metastatic melanoma: a review of therapeutic options

Cancer Immunology, Immunotherapy

Volumn 66, Issue 5, 2017, Pages 647-656

  Weide, Benjamin ^a   Neri, Dario ^b   Elia, Giuliano ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ETH ZURICH   (Switzerland)

^c PHILOCHEM AG   (Switzerland)

Author keywords

CIMT 2016; Immunocytokine; Intralesional; Neoadjuvant; Phase 3; Stage III B C melanoma

Indexed keywords

BCG VACCINE; DARLEUKIN; DAROMUN; DIPHENCYPRONE; FIBROMUN; IMIQUIMOD; IMMUNOCYTOKINE; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC; TOPICAL AGENT; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; METASTATIC MELANOMA; NEOADJUVANT THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CANCER STAGING; MELANOMA; PATHOLOGY; SKIN NEOPLASMS;

ANIMALS; HUMANS; INJECTIONS, INTRALESIONAL; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 85009288493     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1952-0     Document Type: Review

References (61)

1. Geller AC, Annas GD (2003) Epidemiology of melanoma and nonmelanoma skin cancer. Semin Oncol Nurs 19(1):2–11
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
3. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/JCO.2009.23.4799
4. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139(9):961–966. doi:10.1001/archsurg.139.9.961 (discussion 966–967)
5. Lee CC, Faries MB, Wanek LA, Morton DL (2009) Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27(21):3489–3495. doi:10.1200/JCO.2008.18.9845
6. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147(1):62–70
7. Abbott AM, Zager JS (2014) Locoregional therapies in melanoma. Surg Clin North Am 94(5):1003–1015, viii. doi:10.1016/j.suc.2014.07.004
8. Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. doi:10.1200/JCO.2014.58.3377
9. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17):4139–4146. doi:10.1002/cncr.25156
10. Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH Jr (1975) Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36(4):1305–1308
11. Boyd KU, Wehrli BM, Temple CL (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 104(7):711–717. doi:10.1002/jso.21968
12. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G (2009) [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr 100(7):571–585
13. Gutwald JG, Groth W, Mahrle G (1994) Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br J Dermatol 130(4):541–542
14. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626. doi:10.1038/sj.bjc.6601320
15. Weide B, Eigentler TK, Pflugfelder A et al (2014) Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2(7):668–678. doi:10.1158/2326-6066.CIR-13-0206
16. Pretto F, Elia G, Castioni N, Neri D (2014) Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother 63(9):901–910. doi:10.1007/s00262-014-1562-7
17. Marabelle A, Kohrt H, Caux C, Levy R (2014) Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 20(7):1747–1756. doi:10.1158/1078-0432.CCR-13-2116
18. Temizoz B, Kuroda E, Ishii KJ (2016) Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 28(7):329–338. doi:10.1093/intimm/dxw015
19. Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642–662. doi:10.1038/nrd4663
20. Karakousis CP, Douglass HO Jr, Yeracaris PM, Holyoke ED (1976) BCG immunotherapy in patients with malignant melanoma. Arch Surg 111(6):716–718
21. Robinson JC (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9(6):587–593
22. Barth A, Morton DL (1995) The role of adjuvant therapy in melanoma management. Cancer 75(2 Suppl):726–734
23. Seigler HF, Shingleton WW, Pickrell KL (1975) Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; a clinical assessment. Plast Reconstr Surg 55(3):294–298
24. Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100(8):1692–1698. doi:10.1002/cncr.20166
25. Damian DL, Shannon KF, Saw RP, Thompson JF (2009) Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 50(4):266–271. doi:10.1111/j.1440-0960.2009.00556.x
26. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB (2012) Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35(9):716–720. doi:10.1097/CJI.0b013e31827457bd
27. Hemmi H, Kaisho T, Takeuchi O et al (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196–200. doi:10.1038/ni758
28. Walter A, Schafer M, Cecconi V et al (2013) Aldara activates TLR7-independent immune defence. Nat Commun 4:1560. doi:10.1038/ncomms2566
29. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21(1):1–14
30. Bilu D, Sauder DN (2003) Imiquimod: modes of action. Br J Dermatol 149(Suppl 66):5–8
31. Sisti A, Sisti G, Oranges CM (2015) Topical treatment of melanoma skin metastases with Imiquimod: a review. Dermatol Online J 21(2)
32. Florin V, Desmedt E, Vercambre-Darras S, Mortier L (2012) Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 30(4):1641–1645. doi:10.1007/s10637-011-9717-2
33. Buckley DA, Du Vivier AW (2001) The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 145(3):385–405
34. van der Steen PH, Happle R (1993) Topical immunotherapy of alopecia areata. Dermatol Clin 11(3):619–622
35. Damian DL, Saw RP, Thompson JF (2014) Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 109(4):308–313. doi:10.1002/jso.23506
36. He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, Roizman B (1997) Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 71(8):6049–6054
37. Liu BL, Robinson M, Han ZQ et al (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10(4):292–303. doi:10.1038/sj.gt.3301885
38. Hu JC, Coffin RS, Davis CJ et al (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12(22):6737–6747. doi:10.1158/1078-0432.CCR-06-0759
39. Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte–macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763–5771. doi:10.1200/JCO.2009.24.3675
40. Chen L, Daud A (2016) A review of novel intralesional therapies for melanoma, with an emphasis on a potential combination approach. Oncology (Williston Park) 30(5):442–443
41. Agarwala SS (2015) Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol 27(2):151–156. doi:10.1097/CCO.0000000000000158
42. Engeland CE, Grossardt C, Veinalde R et al (2014) CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22(11):1949–1959. doi:10.1038/mt.2014.160
43. Puzanov I, Milhem MM, Minor D et al (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIb-IV melanoma. J Clin Oncol 34(22):2619–2626. doi:10.1200/JCO.2016.67.1529
44. Long GV, Dummer R, Ribas A et al (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol 34, (suppl; abstr TPS9598)
45. Mousavi H, Zhang X, Gillespie S, Wachter E, Hersey P (2006) Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 16:S8
46. Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18(6):405–411. doi:10.1097/CMR.0b013e32831328c7
47. Wiener M, Damian DL, Thompson JF (2008) Systemic phototoxicity following intralesional rose bengal for subcutaneous melanoma metastases. Dermatology 216(4):361–362. doi:10.1159/000117707
48. Thompson JF, Agarwala SS, Smithers BM et al (2015) Phase 2 study of intralesional pv-10 in refractory metastatic melanoma. Ann Surg Oncol 22(7):2135–2142. doi:10.1245/s10434-014-4169-5
49. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147–159. doi:10.1038/nrd1957
50. Johannsen M, Spitaleri G, Curigliano G et al (2010) The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46(16):2926–2935. doi:10.1016/j.ejca.2010.07.033
51. Eigentler TK, Weide B, de Braud F et al (2011) A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17(24):7732–7742. doi:10.1158/1078-0432.CCR-11-1203
52. Spitaleri G, Berardi R, Pierantoni C et al (2013) Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol 139(3):447–455. doi:10.1007/s00432-012-1327-7
53. Papadia F, Basso V, Patuzzo R et al (2013) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107(2):173–179. doi:10.1002/jso.23168
54. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3):751–758. doi:10.1038/jid.2012.376
55. Danielli R, Patuzzo R, Di Giacomo AM et al (2015) Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother 64(8):999–1009. doi:10.1007/s00262-015-1704-6
56. Johnson DB, Sosman JA (2015) Therapeutic advances and treatment options in metastatic melanoma. JAMA Oncol 1(3):380–386. doi:10.1001/jamaoncol.2015.0565
57. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, Kirkwood JM (2008) Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112(5):982–994. doi:10.1002/cncr.23251
58. Lotze MT (1995) Biologic therapy with interleukin-2: Preclinical studies. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, pp 207–233
59. Rosenberg SA, Lotze MT, Yang JC et al (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7(12):1863–1874
60. van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11(4):397–408. doi:10.1634/theoncologist.11-4-397
61. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773–781. doi:10.1200/JCO.2014.57.4756